Fig. 3From: Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary diseaseLong-term (months 3–12) exacerbation rate by treatment group. Long-term (months 3–12) exacerbation rate by treatment group, for patients reporting <2, ≥2, ≥6, or ≥10 inhalations/day in the week preceding the 2-month visit. P-values are for the analysis of BUD/FORM versus FORM. BUD budesonide, FORM formoterolBack to article page